Stanford scientists created an odd couple: a modified version of an immune-signaling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy’s side effects.
Inside Stanford Medicineis a twice-monthly newspaper that reports on the accomplishments and activities of the faculty, staff and students in the Stanford Medicine community. To suggest a story or to get more information, contact editor John Sanford at (650) 723-8309 or email@example.com.
You're receiving this newsletter because you registered with us.
Not interested anymore? Unsubscribe here.